Homology Medicines Inc (NASDAQ:FIXX) CFO W Bradford Smith sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $16.00, for a total transaction of $96,000.00. Following the sale, the chief financial officer now owns 6,000 shares in the company, valued at $96,000. The sale was disclosed in a filing with the SEC, which is available at this link.
W Bradford Smith also recently made the following trade(s):
- On Monday, December 2nd, W Bradford Smith sold 6,000 shares of Homology Medicines stock. The stock was sold at an average price of $16.21, for a total transaction of $97,260.00.
- On Tuesday, October 1st, W Bradford Smith sold 6,000 shares of Homology Medicines stock. The shares were sold at an average price of $17.39, for a total transaction of $104,340.00.
Shares of FIXX traded up $1.18 during mid-day trading on Tuesday, reaching $18.32. 667,880 shares of the stock traded hands, compared to its average volume of 242,386. The firm has a fifty day moving average price of $13.63 and a 200 day moving average price of $17.60. The company has a market cap of $704.55 million, a price-to-earnings ratio of -9.16 and a beta of 0.14. Homology Medicines Inc has a 1 year low of $11.05 and a 1 year high of $31.80.
Several equities research analysts have issued reports on FIXX shares. Oppenheimer assumed coverage on Homology Medicines in a research report on Friday, November 1st. They set a “market perform” rating on the stock. Robert W. Baird began coverage on Homology Medicines in a research report on Monday, September 9th. They issued an “outperform” rating and a $30.00 price target for the company. HC Wainwright set a $36.00 price target on Homology Medicines and gave the company a “buy” rating in a research report on Tuesday, September 24th. FIX began coverage on Homology Medicines in a research note on Thursday, October 31st. They set a “market perform” rating on the stock. Finally, ValuEngine cut Homology Medicines from a “buy” rating to a “hold” rating in a research report on Monday, November 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $31.40.
Several large investors have recently added to or reduced their stakes in FIXX. Aperio Group LLC bought a new stake in shares of Homology Medicines during the 2nd quarter valued at about $34,000. Bank of Montreal Can purchased a new position in shares of Homology Medicines during the second quarter worth about $40,000. Cubist Systematic Strategies LLC bought a new position in shares of Homology Medicines in the second quarter worth approximately $42,000. Marshall Wace LLP bought a new position in shares of Homology Medicines in the first quarter worth approximately $74,000. Finally, Royal Bank of Canada increased its position in shares of Homology Medicines by 300.0% in the second quarter. Royal Bank of Canada now owns 4,000 shares of the company’s stock worth $78,000 after purchasing an additional 3,000 shares during the last quarter. 71.06% of the stock is currently owned by hedge funds and other institutional investors.
About Homology Medicines
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Recommended Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.